A randomized phase III study has reported significant improvements in R0 resection rate and overall survival associated with perioperative cisplatin and 5-fluorouracil treatment compared with surgery alone in patients with gastroesophageal adenocarcinoma. These data support the results of the randomized phase III MAGIC study that reported a 13% 5-year survival benefit from perioperative chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917 (2010).
Ychou, M. et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: a FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol. 29, 1715–1721 (2011).
Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11–20 (2006).
MacDonald, J. et al. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). ASCO Annual Meeting; 2009 [abstract]. J. Clin. Oncol. 27, 4515 (2009).
Sakuramoto, S. et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357, 1810–1820 (2007).
Paoletti, X. et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303, 1729–1737 (2010).
Wagner, A. D. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. Issue 3. Art. No.: CD004064. doi:10.1002/14651858.CD004064.pub3 (2010).
Cunningham, D. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36–46 (2008).
Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D. Cunningham declares associations with the following companies: Merck Serono, Roche, Amgen. T. S. Waddell declares no competing interests.
Rights and permissions
About this article
Cite this article
Waddell, T., Cunningham, D. Perioperative therapy improves gastroesophageal cancer survival. Nat Rev Clin Oncol 8, 450–452 (2011). https://doi.org/10.1038/nrclinonc.2011.87
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.87
